Agenzia Italiana del Farmaco
Updated lists of allergens for specific immunotherapy and diagnosis published following the end of the transitional phase initiated with AIFA Decision DG 2130/2017 - Updated lists of allergens for specific immunotherapy and diagnosis published following the end of the transitional phase initiated with AIFA Decision DG 2130/2017
Updated lists of allergens for specific immunotherapy and diagnosis published following the end of the transitional phase initiated with AIFA Decision DG 2130/2017
Following the withdrawal of some registration procedures on a voluntary basis by the companies concerned, the lists already published following the conclusion of the transitional phase started with AIFA Decision DG 2130/2017 were updated on 2st February 2023.
Specifically, the update concerns the lists of allergens for specific immunotherapy and diagnosis for which companies may continue the procedure for obtaining a marketing authorisation (Annex 1), for which the Agency has issued a refusal to continue the procedure (Annex 2) and for which companies have waived the procedure for obtaining a marketing authorisation (Annex 3).
Published on: 02 February 2023
🎗️ #13ottobre – #AIFA si illumina per la Giornata nazionale di sensibilizzazione sul tumore al seno...
Vai al post →
📍 AIFA a Genova: “Misurare il valore dell’innovazione – Dalla valutazione del farmaco agli esiti di...
Vai al post →
📅 Giornata Mondiale della Salute Mentale | 10 ottobre 2026
AIFA celebra la Giornata mondiale dell...
Vai al post →
🌍 Oggi si celebra la Giornata Mondiale della Consapevolezza PANS/PANDAS e #AIFA si unisce alla camp...
Vai al post →
🤝 Nell’ambito di “AIFA Ascolta”, spazio di confronto e dialogo tra l’Agenzia e le associazioni che ...
Vai al post →
Appropriatezza prescrittiva, revisione delle Note AIFA e dei Piani Terapeutici: questi i principali ...
Vai al post →
